4D-310

Phase 2

4D Molecular Therapeutics, Inc. (FDMT)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

4mo

FDMTPhase 2$1.0B

4D-310 Phase 2 Results Expected

4D-310• Fabry Disease18

Jun 15Estimated

CT.gov

00%

Competitive Landscape

2 competitors in Fabry Disease

Drug Information

Target Indication

Fabry Disease

Clinical Trial

NCT05629559

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

FDMT

4D Molecular Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

EYLEA® (aflibercept) Injection 2 mg (0.05mL)Phase 3

Macular Neovascularization Secondary to Age-Related Macular Degeneration

4D-150 IVT (3E10 vg/eye)Phase 3

Neovascular Age-Related Macular Degeneration (nAMD)

Aflibercept IVTPhase 2

Neovascular (Wet) Age-Related Macular Degeneration

4D-150 IVTPhase 2

Diabetic Macular Edema

4D-125 IVT InjectionPhase 2

X-Linked Retinitis Pigmentosa

View full pipeline